CA2870357A1 - A binding moiety-drug conjugate comprising a hsp90 binding moiety and a cytotoxic effector drug - Google Patents

A binding moiety-drug conjugate comprising a hsp90 binding moiety and a cytotoxic effector drug Download PDF

Info

Publication number
CA2870357A1
CA2870357A1 CA2870357A CA2870357A CA2870357A1 CA 2870357 A1 CA2870357 A1 CA 2870357A1 CA 2870357 A CA2870357 A CA 2870357A CA 2870357 A CA2870357 A CA 2870357A CA 2870357 A1 CA2870357 A1 CA 2870357A1
Authority
CA
Canada
Prior art keywords
sdc
trap
moiety
hsp90
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2870357A
Other languages
English (en)
French (fr)
Inventor
Dinesh U. Chimmanamada
Weiwen Ying
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madrigal Pharmaceuticals Inc
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of CA2870357A1 publication Critical patent/CA2870357A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2870357A 2012-04-16 2013-04-16 A binding moiety-drug conjugate comprising a hsp90 binding moiety and a cytotoxic effector drug Abandoned CA2870357A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261624639P 2012-04-16 2012-04-16
US61/624,639 2012-04-16
US13/843,771 US20140079636A1 (en) 2012-04-16 2013-03-15 Targeted therapeutics
US13/843,771 2013-03-15
PCT/US2013/036783 WO2013158644A2 (en) 2012-04-16 2013-04-16 Targeted therapeutics

Publications (1)

Publication Number Publication Date
CA2870357A1 true CA2870357A1 (en) 2013-10-24

Family

ID=49384217

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2870357A Abandoned CA2870357A1 (en) 2012-04-16 2013-04-16 A binding moiety-drug conjugate comprising a hsp90 binding moiety and a cytotoxic effector drug

Country Status (10)

Country Link
US (4) US20140079636A1 (enExample)
EP (2) EP3466416A3 (enExample)
JP (4) JP6305981B2 (enExample)
KR (4) KR102071857B1 (enExample)
CN (2) CN104470941B (enExample)
AU (4) AU2013249429B2 (enExample)
CA (1) CA2870357A1 (enExample)
HK (1) HK1207098A1 (enExample)
IL (4) IL293316A (enExample)
WO (1) WO2013158644A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100797283B1 (ko) 2001-08-27 2008-01-23 주식회사 포스코 코일 폭 감지 및 위치 조정 기능을 가진 코일 받침대
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2014025395A1 (en) 2012-08-06 2014-02-13 Duke University Compounds and methods for targeting hsp90
US20150337003A1 (en) * 2013-01-18 2015-11-26 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
AU2014318826B2 (en) * 2013-09-10 2019-10-10 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015116774A1 (en) * 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics
AU2015224576A1 (en) * 2014-03-03 2016-09-22 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
US20170136085A1 (en) * 2014-05-29 2017-05-18 Synta Pharmaceuticals Corp. Targeted therapeutics
US10112962B2 (en) * 2014-07-02 2018-10-30 Xavier University Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2016022358A1 (en) * 2014-08-08 2016-02-11 The Regents Of The University Of California Compositions and methods for reactivating latent viral infections
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
DK3179992T3 (da) 2014-08-11 2022-07-11 Acerta Pharma Bv Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
CN106061990B (zh) * 2014-11-28 2019-09-10 四川海思科制药有限公司 一种阿比特龙衍生物及其制备方法和医药用途
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN104800858B (zh) * 2015-04-27 2017-11-21 中国医学科学院基础医学研究所 Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
KR20180112060A (ko) 2016-02-23 2018-10-11 타베다 세라퓨틱스, 인코포레이티드 Hsp90 표적화된 접합체 및 이의 입자 및 제형
US20190060473A1 (en) * 2016-02-29 2019-02-28 Madrigal Pharmaceuticals, Inc. Hsp90 inhibitor drug conjugates
CN113788818A (zh) * 2016-04-06 2021-12-14 密执安大学评议会 Mdm2蛋白质降解剂
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
RU2752677C2 (ru) * 2016-04-12 2021-07-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка вет
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
CA3022512A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
EP4520745A3 (en) 2016-06-23 2025-05-14 Cornell University Double targeted constructs to affect tumor kill
HUE061847T2 (hu) 2016-10-11 2023-08-28 Arvinas Operations Inc Androgén receptor célzott degradálására alkalmas vegyületek és eljárások
CN106748905B (zh) * 2016-12-14 2018-04-13 河南省化工研究所有限责任公司 一种制备2‑氨基乙基磺酰胺盐酸盐的方法
US11241500B2 (en) 2016-12-14 2022-02-08 Tarveda Therapeutics, Inc. HSP90-targeting conjugates and formulations thereof
IL269800B2 (en) 2017-04-05 2025-01-01 Univ Cornell Trifunctional structures with tunable pharmacokinetics used in imaging and antitumor therapies
AU2018289349A1 (en) 2017-06-20 2020-01-02 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
KR20200016875A (ko) * 2017-06-20 2020-02-17 마드리갈 파마슈티칼스 인코포레이티드 표적화 치료제
CN110785165A (zh) * 2017-06-20 2020-02-11 塔弗达治疗有限公司 靶向治疗剂
US20200237746A1 (en) * 2017-06-20 2020-07-30 Tarveda Therapeutics, Inc. Hsp90 targeted conjugates and particle formulations thereof
WO2018236796A1 (en) * 2017-06-20 2018-12-27 Tarveda Therapeutics, Inc. Combination therapies comprising targeted therapeutics
WO2019014600A1 (en) * 2017-07-13 2019-01-17 Plex Pharmaceuticals, Inc. TREATMENT OF ASSOCIATION FOR THE TREATMENT OF CANCER
US20210000966A1 (en) * 2017-12-14 2021-01-07 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
WO2019195384A1 (en) * 2018-04-05 2019-10-10 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CA3094721A1 (en) * 2018-04-05 2019-10-10 Tarveda Therapeutics, Inc. Pharmaceutical compositions with reduced tert-butanol levels
CA3100216A1 (en) * 2018-06-01 2019-12-05 Tarveda Therapeutics, Inc. Combination therapy
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CA3135174A1 (en) * 2019-04-03 2020-10-08 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
WO2021100029A2 (en) * 2019-11-24 2021-05-27 Kashiv Biosciences, Llc Prodrugs of fulvestrant
WO2021202830A2 (en) * 2020-04-01 2021-10-07 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
AU2021273458A1 (en) 2020-05-09 2022-12-01 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
CN116615422A (zh) * 2020-10-14 2023-08-18 珃诺生物医药科技(杭州)有限公司 用于靶向蛋白降解的方法和组合物
JP2023545171A (ja) * 2020-10-14 2023-10-26 ラノック セラピューティクス （ハンジョウ） カンパニー リミテッド 標的化されたタンパク質分解のための方法及び組成物
CN112279813B (zh) * 2020-10-29 2023-02-28 上海中医药大学 1-环己基吡唑啉酮类羧酸酯酶1抑制剂、其制备及应用
EP4291159A1 (en) 2021-02-15 2023-12-20 Propella Therapeutics, Inc. Abiraterone prodrugs
MX2023000926A (es) * 2021-02-25 2023-02-22 Aptabio Therapeutics Inc Nuevo derivado de pirazol.
MX2023013272A (es) * 2021-05-17 2023-11-30 Biohaven Therapeutics Ltd Agentes para tecnicas de conjugacion dirigida y productos conjugados.
JP7662548B2 (ja) 2022-01-21 2025-04-15 東レエンジニアリング株式会社 実装装置および実装方法
CN116064444B (zh) * 2022-08-24 2025-05-06 长兴制药股份有限公司 一种单胺氧化酶及波普瑞韦双环脯氨酸片段的制备方法
WO2024141052A1 (zh) * 2022-12-30 2024-07-04 江苏威凯尔医药科技有限公司 雌激素受体调节剂及其用途
WO2024199473A1 (en) * 2023-03-31 2024-10-03 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
AR132415A1 (es) * 2023-04-14 2025-06-25 Fusion Pharmaceuticals Inc AGENTES RADIOFARMACÉUTICOS DIRIGIDOS A HSP90 EXTRACELULAR (eHSP90) Y USO DE LOS MISMOS
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025199665A1 (en) * 2024-03-23 2025-10-02 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2330611A1 (en) * 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
EP1169319A4 (en) 1999-04-09 2005-02-09 Sloan Kettering Institutefor C METHODS AND COMPOSITIONS FOR DEGRADING AND / OR INHIBITING TYROSINE KINASES BELONGING TO THE HER FAMILY
EP1337275A4 (en) * 2000-11-02 2007-05-09 Sloan Kettering Inst Cancer METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
JP2005520795A (ja) * 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
JP4399265B2 (ja) * 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
US6759416B2 (en) 2002-08-06 2004-07-06 Panorama Research, Inc. Anticancer conjugates of camptothecin and unsaturated fatty acids
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
CA2549463A1 (en) 2002-12-12 2004-07-01 Conforma Therapeutics Corporation Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
CA2553221A1 (en) * 2004-01-22 2005-08-04 Immunomedics, Inc. Folate conjugates and complexes
EP1737825A1 (en) 2004-03-26 2007-01-03 Van Andel Research Institute Geldanamycin and derivatives inhibit cancer invasion and identify novel targets
PT1817295E (pt) 2004-11-18 2013-02-18 Synta Pharmaceuticals Corp Compostos de triazol que modulam a actividade da hsp90
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007053792A2 (en) 2005-11-05 2007-05-10 Amplyx Pharmaceuticals, Inc. Improving the pharmacokinetics of protease inhibitors and other drugs
US8293726B2 (en) * 2005-12-02 2012-10-23 Vianova Labs, Inc. Treatment of cancer and other diseases
GB0526615D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
TWI490212B (zh) 2006-05-25 2015-07-01 Synta Pharmaceuticals Corp 調節ｈｓｐ９０活性之三唑化合物
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
CN1995020B (zh) * 2006-12-12 2010-12-08 东南大学 放射性碘(*i)-17-丙基胺基-17-去甲氧基格尔德霉素及其制备方法
EP2131814A4 (en) * 2007-02-26 2011-08-03 Wisconsin Alumni Res Found POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS
WO2008108386A1 (ja) 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. 医薬組成物
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
EP2200653A2 (en) * 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
EP2323737A2 (en) * 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2010020618A1 (en) * 2008-08-18 2010-02-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Susceptibility to hsp90-inhibitors
WO2010028389A1 (en) * 2008-09-08 2010-03-11 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
WO2011116181A1 (en) * 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
JP5675619B2 (ja) * 2008-09-17 2015-02-25 エンドサイト, インク.Endocyte, Inc. 葉酸拮抗薬の葉酸受容体結合性コンジュゲート
US20110217241A1 (en) 2008-11-14 2011-09-08 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
US8466260B2 (en) * 2009-04-01 2013-06-18 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
CA2769619C (en) * 2009-08-17 2019-04-30 Roche Glycart Ag Targeted immunoconjugates
JP2013510585A (ja) * 2009-11-13 2013-03-28 インフィニティー ファーマシューティカルズ， インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
US20110268722A1 (en) * 2010-04-22 2011-11-03 Siegelin Markus D Combination therapies with mitochondrial-targeted anti-tumor agents
US20130171105A1 (en) * 2010-05-24 2013-07-04 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
RU2013122898A (ru) 2010-10-22 2014-11-27 Университы До Страсбур Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью
WO2012096919A1 (en) 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
EA201391587A1 (ru) * 2011-04-28 2014-08-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Комбинированная терапия на основе hsp90
CA2844809A1 (en) * 2011-08-19 2013-02-28 Synta Pharmaceuticals Corp. Combination cancer therapy of hsp90 inhibitor with antimetabolite
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
CA2926586C (en) 2013-10-11 2020-04-07 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
CA2934030A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs

Also Published As

Publication number Publication date
JP2022000452A (ja) 2022-01-04
CN104470941A (zh) 2015-03-25
US20200316090A1 (en) 2020-10-08
CN104470941B (zh) 2019-09-27
KR102320942B1 (ko) 2021-11-04
US20150139905A1 (en) 2015-05-21
AU2013249429B2 (en) 2017-03-30
AU2017202625A1 (en) 2017-05-11
EP2838909A4 (en) 2016-04-13
JP2018135332A (ja) 2018-08-30
IL262988B (en) 2020-10-29
JP2020011970A (ja) 2020-01-23
JP6949911B2 (ja) 2021-10-13
JP6305981B2 (ja) 2018-04-04
US20170128580A1 (en) 2017-05-11
IL277912A (en) 2020-11-30
IL262988A (en) 2018-12-31
IL277912B (en) 2022-06-01
IL293316A (en) 2022-07-01
US9597343B2 (en) 2017-03-21
JP2015512953A (ja) 2015-04-30
US20140079636A1 (en) 2014-03-20
US10722525B2 (en) 2020-07-28
KR102071857B1 (ko) 2020-01-31
WO2013158644A2 (en) 2013-10-24
KR20200117066A (ko) 2020-10-13
KR20200011581A (ko) 2020-02-03
EP3466416A2 (en) 2019-04-10
KR102163906B1 (ko) 2020-10-12
AU2017202625B2 (en) 2019-06-06
AU2019226169B2 (en) 2021-02-25
AU2019226169A1 (en) 2019-09-26
KR20210132238A (ko) 2021-11-03
KR20150014455A (ko) 2015-02-06
IL235080B (en) 2018-12-31
CN110559446A (zh) 2019-12-13
AU2013249429A1 (en) 2014-10-23
WO2013158644A3 (en) 2014-01-30
AU2021202647A1 (en) 2021-05-27
EP2838909A2 (en) 2015-02-25
HK1207098A1 (en) 2016-01-22
EP3466416A3 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
AU2019226169B2 (en) Targeted therapeutics
US10675360B2 (en) Targeted therapeutics
US9956293B2 (en) Targeted therapeutics
US20210085700A1 (en) Targeted therapeutics
HK40037904A (en) Targeted therapeutics having an hsp90 ligand as binding moiety
HK40005682A (en) A binding moiety-drug conjugate comprising a hsp90 binding moiety and a cytotoxic effector moiety
HK1231766A1 (en) Targeted therapeutics
HK1224598A1 (en) Targeted therapeutics
HK1224598B (en) Targeted therapeutics

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180410

EEER Examination request

Effective date: 20180410

EEER Examination request

Effective date: 20180410

EEER Examination request

Effective date: 20180410

FZDE Discontinued

Effective date: 20231106